Lavue Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 23-10-2024
- Paid Up Capital ₹ 1.10 M
as on 23-10-2024
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 41.22%
(FY 2023)
- Profit -180.34%
(FY 2023)
- Ebitda -46.02%
(FY 2023)
- Net Worth -21.65%
(FY 2023)
- Total Assets 27.59%
(FY 2023)
About Lavue Pharmaceuticals
The Corporate was formerly known as Q-Rexa Pharmaceuticals Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.10 M, as per Ministry of Corporate Affairs (MCA) records.
Darshak Shah, Murali Sistla, and Sameer Paigankar serve as directors at the Company.
- CIN/LLPIN
U74900MH2009PTC196131
- Company No.
196131
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Lavue Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murali Sistla  | Director | 21-Dec-2009 | Current |
| Darshak Shah | Director | 21-Dec-2009 | Current |
| Sameer Paigankar | Director | 30-Sep-2009 | Current |
Financial Performance and Corporate Structure Insights of Lavue Pharmaceuticals.
Lavue Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 41.22% increase. The company also saw a substantial fall in profitability, with a 180.34% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lavue Pharmaceuticals?
In 2023, Lavue Pharmaceuticals had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nutragenix Healthcare Private LimitedActive 7 years 8 monthsDarshak Shah, Murali Sistla and 1 more are mutual person
Pharma-Serv Healthcare Private LimitedActive 20 years 6 monthsDarshak Shah, Murali Sistla and 1 more are mutual person
- Pharma Serv Ventures Private LimitedActive 17 years 6 months
Darshak Shah, Murali Sistla and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lavue Pharmaceuticals?
Lavue Pharmaceuticals has a workforce of 98 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lavue Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lavue Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
